| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
3M Company$162.97
+1.34 (+0.83%)
C 40Pipeline Score Tools & Services · Commercial
Market Cap
79.17 B
EPS
6.04
P/E Ratio
25.07 $
Value Trade
507.34 M
SEC Financials
Q1 2026Dilution Risk
Revenue
6.03 B
Operating CF
574.00 M
Total Assets
35.44 B
Total Liabilities
32.13 B
Equity
3.26 B
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
3.73 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Apr 21, 2026
Overview
Volume
346.81 K
52 Week Range
124.65 - 177.41
% held by Insiders
0.09 %
% held by Institutions
76.44 %
Enterprise Value
86.42 B
Total Shares
522.61 M
Short %
1.84 %
Float Shares
522.08 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C40
Pipeline Score $743M
Pipeline ValueValuation Signal
4
Drugs Scored0.0x
rNPV / MCap Top 59%
Large Pharma (rank 372 of 905)
Percentile Rank3M Company carries a moderate pipeline score (40/100), with $743M risk-adjusted pipeline value, led by 3M CHG/IPA Prep C in Bacterial Reduction Post-product Application (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3M CHG/IPA Prep C Small molecule | Bacterial Reduction Post-product Application | Phase 3 | NCT02203591 | 56% | $375M | COMPLETED | 738 | - | - | Mar 1, 2015 | - | Nov 23, 2020 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MMM
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
3M Company (MMM) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
MMM
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MMM
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MMM
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MMM Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
MMM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-06-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-06-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-06-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-MMM
Apr 27, 2026Global Food & Beverage Disinfection & Cleaning Market Outlook 2025-2035 | North America & Europe Expansion Driven by 3M Company, BASF SE
The global food and beverage industrial disinfection and cleaning market is set to grow significantly, reaching USD 6.1 billion by 2035, driven by heightened hygiene standards and regulatory compliance. Key trends include the adoption of automated sanitation systems and advanced disinfection technologies. Major players in the market include 3M Company and BASF SE, focusing on product innovation and sustainability.
Read more →-MMM
Jan 20, 20263M Reports Fourth-Quarter and Full-Year 2025 Results; Initiates Full-Year 2026 Financial Guidance
3M reported strong financial results for the fourth quarter and full year of 2025, highlighting significant growth and margin expansion. CEO William Brown emphasized the company's commitment to innovation and operational excellence, positioning it for continued success in 2026. However, 3M also faces challenges, including legal liabilities related to PFAS and economic uncertainties.
Read more →Competitive Position
How MMM ranks across every disease it competes inCompetitive Position is a premium feature
See how MMM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial